Related Experiment Video
Updated: Mar 21, 2026
11:25
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
14.2K
Safety considerations when treating myelofibrosis
J M O'Sullivan1, D P McLornan2, C N Harrison1
1a Department of Haematology , Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital , London , UK.
Expert Opinion on Drug Safety
|May 18, 2016
Summary
Janus Kinase (JAK) inhibitors like ruxolitinib offer new treatment options for myelofibrosis (MF). While beneficial, careful management is needed for side effects and treatment resistance in MF patients.
Area of Science:
- Hematology
- Oncology
Background:
- Myelofibrosis (MF) is a clonal disorder characterized by bone marrow fibrosis, cytopenias, and extramedullary hematopoiesis.
- Current management strategies for MF are evolving with the advent of targeted therapies.
Purpose of the Study:
- To discuss the management of myelofibrosis (MF).
- To focus on the efficacy and safety of Janus Kinase (JAK) inhibitors, specifically ruxolitinib.
- To review traditional therapies and emerging JAK inhibitors.
Main Methods:
- Review of Janus Kinase (JAK)1/JAK 2 inhibitor ruxolitinib's efficacy and safety profile.
- Discussion of potential beneficial and detrimental immunosuppressive effects of ruxolitinib.
- Overview of traditional MF therapies including hydroxycarbamide, interferon, immunomodulatory drugs, and androgens.
Main Results:
- Ruxolitinib demonstrates manageable hematological side effects and significant benefits for symptomatic MF patients.
- Other JAK inhibitors like momelotinib show potential for alleviating anemia.
- Some JAK inhibitors have faced withdrawal due to toxicities, such as Wernicke's encephalopathy with Fedratinib.
Conclusions:
- The introduction of JAK inhibitors has expanded therapeutic options for myelofibrosis.
- Ruxolitinib is a valuable treatment for symptomatic MF, but challenges remain for patients with severe thrombocytopenia or those resistant to therapy.
- Optimal management strategies are crucial for patients with MF who lose response or are resistant to JAK inhibitors, especially those with high-risk mutations.
